Investors

    NASDAQ: STEM

      Listed on the NASDAQ Market since 1992, we are committed to       balancing our standards of scientific rigor and clinical integrity with our       corporate imperatives of value creation and long-term business       sustainability.

Corporate Profile

Driven by nearly 20 years of pioneering research and innovation, StemCells, Inc. is at the forefront of a breakthrough approach to treating human disease. We are applying our scientific and industry leadership in stem cell biology to discover, develop and commercialize novel therapeutics and enabling tools and technologies for use in stem cell-based research and drug discovery.
More >>

Learn more about What Sets Us Apart.


StemCells, Inc. has been listed on the NASDAQ Market since 1992.
CEO Podcast
11/19/10  Interview with CEO Martin McGlynn on Proposed Spinal Cord Injury Trial
Letter to Investors
May 2014  Letter to Investors from CEO Martin McGlynn
Recent News
07/18/14StemCells, Inc. Announces Closing of $20 Million Offering
NEWARK, Calif., July 18, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), today announced that it has closed its previously announced offering of common stock and short term warrants. The Company sold a total of 11,299,435 units to two well recognized institutional biotechnology investors and received total proceeds, net of offering expenses and placement agent fees, of approximately $18.7 million. Each unit consists of one share of common stock and a warrant to purchase 0.85 of a share o... 
Printer Friendly Version
07/15/14StemCells, Inc. Announces Proposed $20 Million Offering
NEWARK, Calif., July 15, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), today announced its intent to offer and sell 11,299,435 shares of common stock and short term warrants for the purchase of up to 9,604,520 additional shares of common stock to two well recognized institutional biotechnology investors, subject to market and other conditions, for gross proceeds of $20 million, before deducting placement fees and other offering expenses. StemCells intends to use the net proceeds of the... 
Printer Friendly Version
07/07/14StemCells, Inc. Appoints Dr. Alan Trounson to Board of Directors
NEWARK, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today the appointment of Alan Trounson, Ph.D. to its Board of Directors. Dr. Trounson most recently served as President of The California Institute of Regenerative Medicine (CIRM), the largest scientific funding body for stem cell research in the world. "We are thrilled to welcome Dr. Trounson to our Board," said Martin McGlynn, president and CEO of StemCells, Inc. "His diverse background includes ground... 
Printer Friendly Version
06/23/14StemCells, Inc. President and CEO Martin McGlynn to Present on a Regenerative Medicine Panel at the 2014 BIO International Convention
NEWARK, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will be a panelist at the 2014 BIO International Convention on June 25, 2014 at 4:15 pm PDT. Mr. McGlynn will participate in the panel discussion, "How International Collaboration is Accelerating the Field." This panel will showcase examples of international collaboration that are producing results or initiating new approaches to cross-border research. Under Mr. M... 
Printer Friendly Version
More >>
Upcoming Events
There are currently no events scheduled.
More >>
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever StemCells, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Enter your e-mail address here:

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
STEM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.70
Change (%) Stock is Up 0.05 (3.03%)
Volume1,365,168
Data as of 07/29/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Analyst Coverage

Click here for a list of analysts covering StemCells, Inc.

Primary IR Contact

Greg Schiffman
CFO
StemCells, Inc.
7707 Gateway Blvd
Newark, CA 94560
Phone: 510.456.4128
Fax: 650.475.3101
Contact by e-mail



Investor Tools
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet